What Rare Patient-Investors Can Learn From Venture Capitalists

RARECast - A podcast by RARECast - Thursdays

Categories:

Fulcrum Therapeutics is working to develop small molecule drugs to modulate gene activity as a way to treat certain rare diseases. The company, established by the venture capital firm Third Rock Ventures, is initially focusing on Fragile X and a form of muscular dystrophy known as FSHD. We spoke to Walt Kowtoniuk, director of strategy and operations for Fulcrum, about its approach, what he learned working in a venture capital firm, and what advice he would offer rare disease patients turned investors.